JP2010520186A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520186A5 JP2010520186A5 JP2009551256A JP2009551256A JP2010520186A5 JP 2010520186 A5 JP2010520186 A5 JP 2010520186A5 JP 2009551256 A JP2009551256 A JP 2009551256A JP 2009551256 A JP2009551256 A JP 2009551256A JP 2010520186 A5 JP2010520186 A5 JP 2010520186A5
- Authority
- JP
- Japan
- Prior art keywords
- buprenorphine
- naloxone
- composition
- patient
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 claims 10
- 229960001736 buprenorphine Drugs 0.000 claims 10
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 7
- 229960004127 Naloxone Drugs 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 210000002381 Plasma Anatomy 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- SFNLWIKOKQVFPB-KZCPYJDTSA-N Bunavail Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C.C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 SFNLWIKOKQVFPB-KZCPYJDTSA-N 0.000 claims 1
- 210000004207 Dermis Anatomy 0.000 claims 1
- 230000000202 analgesic Effects 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
Claims (11)
- 非経口の単位投薬形態または粘膜もしくは真皮を介する送達のために適切な単位投薬形態における鎮痛性組成物であって、ブプレノルフィンおよび患者に送達されるかまたは患者の血漿に到達するブプレノルフィン対ナロキソンの重量による比率が７．５：１〜１２．４：１の範囲中であるような量のナロキソンを含む組成物。
- 前記比率が少なくともＸ：１であり、式中Ｘは８．０または９．０または９．５または１０．０または１０．５または１１．０である、請求項１に記載の組成物。
- 前記比率がＹ：１までであり、式中Ｙは１２．３または１２．２または１２．０または１１．５である、請求項１または２に記載の組成物。
- 前記単位投薬形態中のブプレノルフィンの量は１０μｇ〜８ｍｇまでである、請求項１に記載の組成物。
- ヒト患者の疼痛を治療するための、請求項１に記載の組成物。
- 前記ブプレノルフィンの投与が２４時間あたり体重１ｋｇあたり０．２５〜６４０μｇの範囲中である、請求項５に記載の組成物。
- 疼痛の治療のための医薬品の製造におけるナロキソンおよびブプレノルフィンの使用であって、ナロキソンおよびブプレノルフィンが、７．５：１〜１２．４：１の範囲中のブプレノルフィン対ナロキソンの重量による比率で医薬品が患者に送達されるかまたは患者の血漿中で到達するような量で使用される、ナロキソンおよびブプレノルフィンの使用。
- 前記医薬品がヒト患者の疼痛の治療用であり、非経口又は真皮又は粘膜経路により投与される、請求項７に記載の使用。
- 前記ブプレノルフィンの投与が２４時間あたり体重１ｋｇあたり０．２５〜６４０μｇの範囲中である、請求項７又は８に記載の使用。
- 非ヒト患者における疼痛の治療のための方法であって、患者に送達されるかまたは患者の血漿に到達するブプレノルフィン対ナロキソンの重量による比率が７．５：１〜１２．４：１の範囲中であるようなブプレノルフィンおよびナロキソンの非経口経路または皮膚経路または粘膜経路による非ヒト患者への投与を含む方法。
- 前記ブプレノルフィンの投与が２４時間あたり体重１ｋｇあたり０．２５〜６４０μｇの範囲中である、請求項１０に記載の方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0703968A GB2447016A (en) | 2007-03-01 | 2007-03-01 | Buprenorphine/naloxone compositions |
| PCT/GB2008/000526 WO2008104738A1 (en) | 2007-03-01 | 2008-02-15 | Improvements in and relating to medicinal compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014123827A Division JP2014196325A (ja) | 2007-03-01 | 2014-06-16 | 医薬組成物における改善および医薬組成物に関する改善 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520186A JP2010520186A (ja) | 2010-06-10 |
| JP2010520186A5 true JP2010520186A5 (ja) | 2011-03-31 |
Family
ID=37965735
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551256A Pending JP2010520186A (ja) | 2007-03-01 | 2008-02-15 | 医薬組成物における改善および医薬組成物に関する改善 |
| JP2014123827A Abandoned JP2014196325A (ja) | 2007-03-01 | 2014-06-16 | 医薬組成物における改善および医薬組成物に関する改善 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014123827A Abandoned JP2014196325A (ja) | 2007-03-01 | 2014-06-16 | 医薬組成物における改善および医薬組成物に関する改善 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20110046172A1 (ja) |
| EP (1) | EP2129380A1 (ja) |
| JP (2) | JP2010520186A (ja) |
| KR (1) | KR20090117891A (ja) |
| CN (1) | CN101626766B (ja) |
| AR (1) | AR065579A1 (ja) |
| AU (1) | AU2008220574A1 (ja) |
| BR (1) | BRPI0807908A2 (ja) |
| CA (1) | CA2678582A1 (ja) |
| CL (1) | CL2008000606A1 (ja) |
| GB (1) | GB2447016A (ja) |
| HK (1) | HK1139871A1 (ja) |
| MX (1) | MX2009009131A (ja) |
| PE (1) | PE20090168A1 (ja) |
| TW (1) | TWI451868B (ja) |
| WO (1) | WO2008104738A1 (ja) |
| ZA (1) | ZA200905664B (ja) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US8663687B2 (en) | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
| UA102128C2 (en) * | 2008-12-05 | 2013-06-10 | Х. Луннбек А/С | Nalmefene hydrochloride dihydrate |
| US8475832B2 (en) * | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| WO2011112956A1 (en) * | 2010-03-12 | 2011-09-15 | Government Of The Usa, As Represented By The Sec., Dept. Of Health And Human Services | Agonist/antagonist compositions and methods of use |
| US8529914B2 (en) * | 2010-06-28 | 2013-09-10 | Richard C. Fuisz | Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| ES2660116T3 (es) * | 2011-08-18 | 2018-03-20 | Biodelivery Sciences International, Inc. | Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina |
| DK2706986T3 (en) | 2011-09-19 | 2015-06-01 | Orexo Ab | NEW ADDICTION PREVENTING PHARMACEUTICAL COMPOSITION FOR TREATMENT OF OPIOID ADDICTION |
| SG10202012743WA (en) * | 2011-12-21 | 2021-01-28 | Biodelivery Sciences Int Inc | Transmucosal drug delivery devices for use in chronic pain relief |
| CN103690495B (zh) * | 2013-12-19 | 2015-04-08 | 贵州景峰注射剂有限公司 | 注射用盐酸纳洛酮的冷冻干燥方法 |
| ES2631504B1 (es) | 2014-03-14 | 2018-11-28 | Opiant Pharmaceuticals, Inc. | Medicamentos de administración nasal y métodos para su uso |
| US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| JP2019519487A (ja) | 2016-05-05 | 2019-07-11 | アクエスティブ セラピューティクス インコーポレイテッド | 送達増強エピネフリン組成物 |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| JPH1036265A (ja) * | 1996-07-19 | 1998-02-10 | Nitto Denko Corp | ブプレノルフィン経皮吸収製剤 |
| AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| DK1526848T3 (da) * | 2002-08-09 | 2007-10-22 | Gruenenthal Gmbh | Opiod-receptorantagonister i transdermale systemer med buprenorphin |
| US20050191340A1 (en) * | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
-
2007
- 2007-03-01 GB GB0703968A patent/GB2447016A/en not_active Withdrawn
-
2008
- 2008-02-15 CN CN2008800068666A patent/CN101626766B/zh not_active Expired - Fee Related
- 2008-02-15 MX MX2009009131A patent/MX2009009131A/es not_active Application Discontinuation
- 2008-02-15 KR KR1020097018305A patent/KR20090117891A/ko not_active Application Discontinuation
- 2008-02-15 BR BRPI0807908-0A2A patent/BRPI0807908A2/pt not_active IP Right Cessation
- 2008-02-15 CA CA002678582A patent/CA2678582A1/en not_active Abandoned
- 2008-02-15 AU AU2008220574A patent/AU2008220574A1/en not_active Abandoned
- 2008-02-15 EP EP08709417A patent/EP2129380A1/en not_active Withdrawn
- 2008-02-15 WO PCT/GB2008/000526 patent/WO2008104738A1/en active Application Filing
- 2008-02-15 JP JP2009551256A patent/JP2010520186A/ja active Pending
- 2008-02-15 US US12/529,171 patent/US20110046172A1/en not_active Abandoned
- 2008-02-27 TW TW097106779A patent/TWI451868B/zh not_active IP Right Cessation
- 2008-02-28 CL CL200800606A patent/CL2008000606A1/es unknown
- 2008-02-29 AR ARP080100880A patent/AR065579A1/es not_active Application Discontinuation
- 2008-02-29 PE PE2008000413A patent/PE20090168A1/es not_active Application Discontinuation
-
2009
- 2009-08-14 ZA ZA200905664A patent/ZA200905664B/xx unknown
-
2010
- 2010-07-06 HK HK10106544.6A patent/HK1139871A1/xx not_active IP Right Cessation
-
2014
- 2014-06-16 JP JP2014123827A patent/JP2014196325A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520186A5 (ja) | ||
| JP2010520183A5 (ja) | ||
| HK1139871A1 (en) | Improvements in and relating to medicinal compositions | |
| MX2009009132A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. | |
| JP2010520185A5 (ja) | ||
| CA2661759A1 (en) | Buprenophine-wafer for drug substitution therapy | |
| IL203747A (en) | Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it | |
| JP2010520184A5 (ja) | ||
| JP2003514013A5 (ja) | ||
| JP2009544619A5 (ja) | ||
| JPWO2006016530A1 (ja) | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 | |
| JP2009280627A5 (ja) | ||
| SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
| MX2011013902A (es) | Tratamiento de esclerosis multiple con laquinimod. | |
| HRP20140591T1 (hr) | Poboljšani medicinski pripravci koji sadrže buprenorfin i nalmefen | |
| MX2009009133A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona. | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2008534503A5 (ja) | ||
| SI1715859T1 (sl) | Postopek za zdravljenje in diagnosticiranje motenega dihanja med spanjem z uporabo zonisamida in sredstvo za izvedbo postopka | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2013541583A5 (ja) | ||
| RU2007101695A (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
| JP2016505050A5 (ja) | ||
| JP2011500589A5 (ja) |